Book Abstract
Gastric Cancer: From Molecular Insights to Clinical Management provides a unified, contemporary framework?from genomic subtyping and biomarker-driven therapy to advanced imaging, microbiome modulation, and multi-omic precision. It equips oncologists, pathologists, and researchers with tools to deliver tailored, cutting-edge care and enhance patient outcomes in gastric carcinoma.
Gastric cancer (GC) remains a major global health challenge, ranking among the top five most common cancers with poor survival rates due to late-stage presentation. Gastric Cancer: From Molecular Insights to Clinical Management integrates breakthroughs in tumor biology, diagnostic technology, and therapeutic innovation, offering a cohesive guide toward precision-driven patient care.
Modern molecular taxonomy?spanning MSI-high, EBV-positive, chromosomal instability, and genomically stable GC?enables accurate stratification for targeted treatment. Key biomarkers now include HER2, PD-L1 CPS, MET amplifications, NTRK/BRAF/RET fusions, lncRNAs such as HIF1A-AS2 and GAPLINC, STAT3 pathway alterations, and CAMSAP2-mediated TGF-? signaling?all critical for prognosis and therapy selection.
Combining genomics, epigenetics, proteomics, metabolomics, and transcriptomics enables personalized treatment planning. Predictive AI models (e.g., iMD4GC) aid in forecasting response to therapies, including neoadjuvant chemotherapy.
